RecruitingPhase 2NCT06133101

Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)


Sponsor

Marialena Mouzaki

Enrollment

44 participants

Start Date

Jan 15, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

A randomized, controlled study of standard soy milk consumption compared to 2% fat cow's milk consumption in children with Non-alcoholic Fatty Liver Disease (NAFLD). The investigators hypothesize that the daily consumption of soy isoflavones found in the soy milk will be beneficial in reducing NAFLD and other obesity-related comorbidities. The investigators do not expect any adverse endocrine or metabolomic effects from the consumption of soy isoflavones.


Eligibility

Min Age: 5 YearsMax Age: 12 Years

Inclusion Criteria3

  • Children with overweight/obesity
  • Non-alcoholic fatty liver disease (NAFLD) and an MRI PDFF >10%
  • Known NAFLD or elevated ALT for sex (>22 for females and >26 for males)

Exclusion Criteria6

  • MRI-PDFF <10%
  • Baseline habitual (>3 days per week) consumption of soy foods
  • Allergy to soy or cow's milk protein
  • Inability to undergo MRI
  • Recent (past 8 weeks) antibiotic exposure
  • Treatment for existing endocrine disorders

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGStandard Soy Milk

Consumption of commercially available soy milk

DRUG2% Fat Cow's Milk

Consumption of commercially available 2% cow's milk


Locations(1)

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06133101


Related Trials